ML327
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H407921

CAS#: 1883510-31-3

Description: ML327 is a blocker of MYC. ML327 mediated transcriptional de-repression of E-cadherin and inhibition of epithelial-to-mesenchymal transition. ML327 induces apoptosis and sensitizes Ewing sarcoma cells to TNF-related apoptosis-inducing ligand. ML327 blocks MYC expression and tumor formation in neuroblastoma.


Chemical Structure

img
ML327
CAS# 1883510-31-3

Theoretical Analysis

Hodoodo Cat#: H407921
Name: ML327
CAS#: 1883510-31-3
Chemical Formula: C19H18N4O4
Exact Mass: 366.13
Molecular Weight: 366.377
Elemental Analysis: C, 62.29; H, 4.95; N, 15.29; O, 17.47

Price and Availability

Size Price Availability Quantity
50mg USD 550 2 Weeks
100mg USD 950 2 Weeks
200mg USD 1450 2 Weeks
500mg USD 2450 2 Weeks
1g USD 3250 2 Weeks
2g USD 5250 2 Weeks
Bulk inquiry

Synonym: ML-327; ML 327; ML327.

IUPAC/Chemical Name: N-(3-(2-oxo-1,2-dihydropyridine-3-carboxamido)propyl)-5-phenylisoxazole-3-carboxamide

InChi Key: NNNDNXLMQAPQQQ-UHFFFAOYSA-N

InChi Code: InChI=1S/C19H18N4O4/c24-17-14(8-4-9-20-17)18(25)21-10-5-11-22-19(26)15-12-16(27-23-15)13-6-2-1-3-7-13/h1-4,6-9,12H,5,10-11H2,(H,20,24)(H,21,25)(H,22,26)

SMILES Code: C1C=CNC(=O)C=1C(=O)NCCCNC(=O)C1=NOC(C2=CC=CC=C2)=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 366.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Padmanabhan C, Rellinger EJ, Zhu J, An H, Woodbury LG, Chung DH, Waterson AG, Lindsley CW, Means AL, Beauchamp RD. cFLIP critically modulates apoptotic resistance in epithelial-to-mesenchymal transition. Oncotarget. 2017 Jul 25;8(60):101072-101086. doi: 10.18632/oncotarget.19557. eCollection 2017 Nov 24. PubMed PMID: 29254146; PubMed Central PMCID: PMC5731856.

2: Rellinger EJ, Padmanabhan C, Qiao J, Craig BT, An H, Zhu J, Correa H, Waterson AG, Lindsley CW, Beauchamp RD, Chung DH. Isoxazole compound ML327 blocks MYC expression and tumor formation in neuroblastoma. Oncotarget. 2017 Jul 20;8(53):91040-91051. doi: 10.18632/oncotarget.19406. eCollection 2017 Oct 31. PubMed PMID: 29207623; PubMed Central PMCID: PMC5710904.

3: Rellinger EJ, Padmanabhan C, Qiao J, Appert A, Waterson AG, Lindsley CW, Beauchamp RD, Chung DH. ML327 induces apoptosis and sensitizes Ewing sarcoma cells to TNF-related apoptosis-inducing ligand. Biochem Biophys Res Commun. 2017 Sep 16;491(2):463-468. doi: 10.1016/j.bbrc.2017.07.050. Epub 2017 Jul 14. PubMed PMID: 28716733; PubMed Central PMCID: PMC5564678.

4: Stoops SL, Waterson AG, An H, Deane N, Daniels JS, Morrison R, Engers JL, Beauchamp D, Lindsley CW. Discovery and characterization of a small molecule that restores E-cadherin expression in cancer cell lines via a new mechanism. 2012 Dec 13 [updated 2013 Mar 22]. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-. Available from http://www.ncbi.nlm.nih.gov/books/NBK344134/ PubMed PMID: 26913352.

5: Brogan JT, Stoops SL, Brady S, An H, Weaver C, Daniels JS, Beauchamp RD, Lindsley CW, Waterson AG. Optimization of a small molecule probe that restores e-cadherin expression. Bioorg Med Chem Lett. 2015 Oct 1;25(19):4260-4. doi: 10.1016/j.bmcl.2015.07.104. Epub 2015 Aug 6. PubMed PMID: 26299347; PubMed Central PMCID: PMC4567403.

6: An H, Stoops SL, Deane NG, Zhu J, Zi J, Weaver C, Waterson AG, Zijlstra A, Lindsley CW, Beauchamp RD. Small molecule/ML327 mediated transcriptional de-repression of E-cadherin and inhibition of epithelial-to-mesenchymal transition. Oncotarget. 2015 Sep 8;6(26):22934-48. PubMed PMID: 26082441; PubMed Central PMCID: PMC4673210.